December 9, 2019 09:35 AM ESTUpdated 04:04 PM

KalVista's diabetic macular edema data falls short — will Merck walk away?

Natalie Grover

Reporter

Merck’s 2017 bet on KalVista Pharmaceuticals may have soured, after the UK/US-based biotech’s lead drug failed a mid-stage study in patients with diabetic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

KalVista's diabetic macular edema data falls short — will Merck walk away?

Natalie Grover

Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

KalVis­ta's di­a­bet­ic mac­u­lar ede­ma da­ta falls short — will Mer­ck walk away?

Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

KalVista's diabetic macular edema data falls short — will Merck walk away?